Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir®

Inclusion Criteria: * Written informed consent * Healthy male 18-45 years old * Documented negative test for HIV-1 infection \< 1 wk prior to start of study and with no risk of HIV exposure in the last 6 months * BMI 18-25 * Normal physical examination * Normal CBC, BUN, Cr, AST, ALT, Total bilirubin, no evidence of active or chronic HBV or HCV infection Exclusion Criteria: * History of sensitivity/idiosyncrasy to the drug or chemically related compounds or excipients, which may be employed in the study. * Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion. * Inability to understand the nature and extent of the study and the procedures required. * Participation in a drug study within 60 days prior to the first dose. * Febrile illness within 3 days before the first dose. * Use of concomitant medication * Smoke cigarettes not more than 10 cigarettes a day. * Drink alcohol not more than 2 units a day. * Discontinue smoking and alcohol for at least 1 month before enrollment. * Take other medication regularly * Involvement in any drug addiction. * Heart disease, hypertension, liver disease, kidney disease, GI disease, allergic disease or other diseases which may interfere with the PK of study drugs